Asia Pacific Breast Reconstruction Market is expected to reach US$ 184.9 Mn by 2028

Inframammary Segment has the Largest Share of Technology in the Asia Pacific Breast Reconstruction Market during 2021–2028

According to The Insight Partners market research study on “Asia Pacific Breast Reconstruction Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Technology, Type, Placement and Procedure,” is expected to reach US$ 184.9 million by 2028 from US$ 117.7 million in 2021. The market is estimated to grow at a CAGR of 6.7% from 2021 to 2028. The report provides trends prevailing in the Asia Pacific breast reconstruction market along with the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the high prevalence of breast cancer and new product launches and FDA approvals are the key factors driving the market growth. However, the market is expected experiencing slow growth during the forecast period owing to the low awareness regarding reimbursement policies.

Asia Pacific countries are expecting to witness huge challenge due to growing COVID-19. Due to outbreak of disease, healthcare industries have been affected badly, considering the economic conditions in current situation. Due to growing coronavirus cases, many seminars and international conference has been postponed. For instance, 9th Asia Pacific Breast Cancer Summit has been postponed after 13th to 15th march due to current growing coronavirus. Restrictive measures have been taken to control the spread of this pandemic, however, in this measure’s cancer patients are not being treated on priority. For instance, according to Japanese report of 2020, “more than half of breast surgeries and breast reconstructions had to be postponed during the COVID-19 pandemic, and the number of candidates for surgery was also lower compared to the pre-pandemic periods. Triage of patients with breast cancer did not result in any adverse oncological outcomes for these patients. COVID-19 has had a major impact on breast cancer surgery and breast reconstruction, and there was substantial postponement of surgery. Apart from overall health system, cancer care delivery system has been facing challenges due to coronavirus outbreak.

The market for breast reconstruction market is segmented into technology, type, placement, and procedure. Based on technology, the breast reconstruction market is segmented into inframammary, peri-areolar, trans-axillary, and transumbilical. In 2020, the inframammary by technology segment accounted for the largest share of the market. Growth of this segment is attributed to rising emphasis on aesthetic appearance and rising number of product launches. However, peri-areolar technology segment is estimated to register the highest CAGR during the forecast period.

Allergan Plc, Mentor Worldwide LLC (Subsidiary of Johnson & Johnson), GC Aesthetics PLC, POLYTECH Health & Aesthetics GmbH, HANSBIOMED CO. LTD, Establishment Labs S.A., Guangzhou Wanhe Plastic Materials Co., Ltd., and Groupe Sebbin SAS are among the leading companies in the Asia Pacific breast reconstruction market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in May 2020, AbbVie announced that it has completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court.

The report segments the Asia Pacific Breast Reconstruction market as follows:

By Technology

• Inframammary
• Peri-Areolar
• Trans-Axillary
• Transumbilical

By Type

• Breast Implants
• Implant’s accessories

By Placement

• Dual Plane Insertion
• Subglandular Insertion
• Submuscular Insertion

By Procedure

• Immediate Procedures
• Delayed Procedures
• Revision Procedures

By Country

• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Rest of Asia Pacific